1 / 30

Prequel: Some Useful Information

Prequel: Some Useful Information. Everything you need to know is on the Web at: www.fda.gov Hint: If you are not happy with “sort by relevance” Switch the search tool to “sort by date.”. The Good Review Management Practice Guidance -- A Statistical Reviewer’s Perspective.

peri
Download Presentation

Prequel: Some Useful Information

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prequel: Some Useful Information Everything you need to know is on the Web at: www.fda.gov Hint: If you are not happy with“sort by relevance” Switch the search tool to “sort by date.”

  2. The Good Review Management Practice Guidance -- A Statistical Reviewer’s Perspective Steve Wilson, Dr.P.H., CAPT USPHS Deputy Director, Division of Biometrics II, CDER/FDA ASA Biopharmaceutical Section -- FDA/Industry Workshop Marriott Wardman Park, Washington, DC September 16 , 2005

  3. Disclaimer Views expressed in this presentation are those of the speaker and not, necessarily, of the Food and Drug Administration.

  4. Acknowledgements • Dave Christiansen • Ruthie Davi • Ed Nevius • ADaM Workgroup

  5. Outline • Statistical Review • Good Review Management Practice Guidance • Time for Change • Pre-NDA Statistics Meeting • Meta-Data Standards for Analysis • Statistical Guidance

  6. Statistical Review • Assess quality / completeness of data • Assess compliance with protocol / blinded analysis plans -- conduct of the study • Check appropriateness of statistical models and conclusions • Verify results reported in the NDA • Answer new review-related questions • Examine individual patient experience during clinical trial

  7. A Review Tale

  8. New Guidance Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) April 2005 Procedural

  9. GRMP: Operational Principles • The foundation for good review management is created during product development. • The applicant is responsible for submission of a complete marketing application to maximize the efficiency of the review process and reduce the need for multiple cycle reviews. • Effective and efficient management of the review process is primarily an FDA responsibility.

  10. GRMP : Operational Principles (cont.) • Active applicant involvement is important during the review process. • Good review management increases first cycle approvals. • Effective and timely communication between the FDA and applicants enhances the review process

  11. GRMP: Fundamental Values • Quality • Efficiency • Clarity • Transparency • Consistency • Mom • Apple Pie • No Surprises

  12. GRMP:FDA Reviewing Steps • Application completeness • Pre-submission • Application receipt • Filing • Review Planning • Review • Advisory Committee • Wrap-up and Labeling • Action

  13. Application Receipt CDR assigns NDA/BLA no. EOP2 Mtg. Pre-NDA Mtg. Filing Guidance for Good Review Management Principles for PDUFA Products Presubmission Fileabiliy Evaluation Encourage Regular Mtgs. Acknowledgement Letter Request Consults Assignment of Review Team, Review Priority, Signature Authority Scientific & Reg. Advice Inform of Filing Deficiencies Submit App & User Fee Background Packages Respond to Filing Deficiencies Davi, 2005

  14. Labeling Negotiations Final Division & Office Eval. & Action Filing AC Mtg. Guidance for Good Review Management Principles for PDUFA Products Application Filed and Under Review Primary & Secondary Review IR/DR Letters AC Backgrounder, Questions, & Prep. Evaluate & Incorporate AC advice Labeling Negotiation Schedule AC AC Preparations Schedule AC Labeling Negotiation Planned Amendments (safety update) Respond to IR/DR Letters Davi, 2005

  15. The Shoe is on the Other Foot

  16. Time for a Change? Is the GRMP another annoying regulatory/management burden? or “An OPPORTUNITY disguised as a PROBLEM*”? J. Michael

  17. Industry/FDA Statisticians:Like an Old Married Couple?

  18. Changes/Opportunities • Can we change? • What do we change? • How do we change? • Can we get better?

  19. If I Ran the Zoo

  20. If I Ran the Zoo:Some of the Changes That I Would Like to See • Earlier/Better Communication: A Pre-NDA Statistics Meeting • Metadata Standards for Data and Analysis • More Guidance Relating to Statistics for Therapeutic Areas • Required Electronic Submission using the e-CTD (IND and NDA/CTD) • Technology-supported Tools for the IR/DR Process • “Adult Conversation” -- Sponsors submissions including reviews

  21. Labeling Negotiations Final Division & Office Eval. & Action Filing AC Mtg. GRMP: Earlier/Better Communication Application Filed and Under Review Primary & Secondary Review IR/DR Letters AC Backgrounder, Questions, & Prep. Evaluate & Incorporate AC advice Labeling Negotiation Schedule AC AC Preparations Schedule AC Labeling Negotiation Planned Amendments (safety update) Respond to IR/DR Letters Davi, 2005

  22. Application Receipt CDR assigns NDA/BLA no. EOP2 Mtg. Pre-NDA Mtg. Filing GRMP: A Pre-NDA Statistics Meeting Presubmission Fileabiliy Evaluation Encourage Regular Mtgs. Acknowledgement Letter Request Consults Assignment of Review Team, Review Priority, Signature Authority Scientific & Reg. Advice Inform of Filing Deficiencies Submit App & User Fee Background Packages Respond to Filing Deficiencies Davi, 2005

  23. Pre-NDA Statistics Meeting • Why not include in existing Pre-NDA meeting? • Wrong audience – (The bored and the lost) • No time – technical issues get moved to the end of the agenda • Timing - may be too early or too late • Will it add value? • Yes – it is necessary • How will it affect reviewers/sponsors processes and procedures?

  24. Pre-NDA Statistics Topics • Review proposed primary analyses • Review proposed ADaM and SDTM datasets • Discuss what additional analyses and ADaM datasets might be useful (“Review Analysis Files”) • Discuss submission of programs • Analysis dataset creation programs • Analysis generation programs • Timing and functionality of submission of programs • Evaluate “test data” – “pre-e-Submission”

  25. Pre-e-Submission Data and Metadata • Provides valuable feedback to sponsor • Allows agency to test compatibility with standard tools and databases • Tests content and structure of metadata, documentation and programs • Identifies technical problems early • Highlights possible areas of misunderstanding and differences in interpretation • “Tunes” in the reviewer

  26. How to Provide “Clear Communication” • Use the eCTD to provide a common organization and structure to the document. • Makes components easy to find • Allows standard tools to be used for navigation, browsing • Use ADaM and SDTM dataset standards and metadata to describe the submitted data • Common look and feel for data, both within and across submissions • Allows standard tools to be used for navigation, browsing and analysis

  27. Metadata Standards for Data and Analysis • Enable reviewers to understand, replicate, explore, confirm, reuse, etc. • Clear, unambiguous communication of decisions, analysis and results • Underlying principles: • Can a reviewing statistician understand? • Can a reviewing statistician efficiently: • Quality Assure? • Validate? • Analyze?

  28. Metadata Standards for Data and Analysis • Analysis • Analysis Datasets • Analysis Variables • Programs

  29. More Statistical Guidance:General Principles & Therapy-Specific

  30. GRMP: Motivates All of Us to Wear the Same Better \Faster Shoes

More Related